Glenmark Pharmaceuticals Ltd vs Morepen Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 11, 2026

Key Highlights

The Latest Trading Price of Glenmark Pharmaceuticals Ltd is ₹ 2144 as of 11 Jun 15:30 . The P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 13.5 on March 2021 to 41.5 on March 2025 . This represents a CAGR of 25.18% over 5 yearsThe P/E Ratio of Morepen Laboratories Ltd changed from 14.9 on March 2021 to 22.3 on March 2025 . This represents a CAGR of 8.40% over 5 years The Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 13108 crore on March 2021 to ₹ 43458 crore on March 2025 . This represents a CAGR of 27.09% over 5 yearsThe Market Cap of Morepen Laboratories Ltd changed from ₹ 1446 crore on March 2021 to ₹ 2621 crore on March 2025 . This represents a CAGR of 12.64% over 5 years The revenue of Glenmark Pharmaceuticals Ltd for the Mar '26 is ₹ 3959 crore as compare to the Dec '25 revenue of ₹ 3945 crore. This represent the growth of 0.37% The revenue of Morepen Laboratories Ltd for the Mar '26 is ₹ 493.18 crore as compare to the Dec '25 revenue of ₹ 487.97 crore. This represent the growth of 1.07% The ebitda of Glenmark Pharmaceuticals Ltd for the Mar '26 is ₹ 578.28 crore as compare to the Dec '25 ebitda of ₹ 729.88 crore. This represent the decline of -20.77% The ebitda of Morepen Laboratories Ltd for the Mar '26 is ₹ 32.91 crore as compare to the Dec '25 ebitda of ₹ 50.12 crore. This represent the decline of -34.34% The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 340.24 crore to ₹ 301.32 crore over 8 quarters. This represents a CAGR of -5.89% The net profit of Morepen Laboratories Ltd changed from ₹ 36.17 crore to ₹ 15.7 crore over 8 quarters. This represents a CAGR of -34.12% The Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 4.28 % on March 2021 to 4.38 % on March 2025 . This represents a CAGR of 0.46% over 5 yearsThe Dividend Payout of Morepen Laboratories Ltd changed from 10.79 % on March 2025 to 10.79 % on March 2025 . This represents a CAGR of 0.00% over 1 years .

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
Its branded generics business has a significant presence in markets across emerging economies including India.

About Morepen Laboratories Ltd

Morepen Laboratories Limited is an India-based pharmaceutical company.
Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin.
The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast.
It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India.
The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally.

FAQs for the comparison of Glenmark Pharmaceuticals Ltd and Morepen Laboratories Ltd

Which company has a larger market capitalization, Glenmark Pharmaceuticals Ltd or Morepen Laboratories Ltd?

Market cap of Glenmark Pharmaceuticals Ltd is 60,513 Cr while Market cap of Morepen Laboratories Ltd is 2,590 Cr

What are the key factors driving the stock performance of Glenmark Pharmaceuticals Ltd and Morepen Laboratories Ltd?

The stock performance of Glenmark Pharmaceuticals Ltd and Morepen Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glenmark Pharmaceuticals Ltd and Morepen Laboratories Ltd?

As of June 11, 2026, the Glenmark Pharmaceuticals Ltd stock price is INR ₹2144.35. On the other hand, Morepen Laboratories Ltd stock price is INR ₹47.27.

How do dividend payouts of Glenmark Pharmaceuticals Ltd and Morepen Laboratories Ltd compare?

To compare the dividend payouts of Glenmark Pharmaceuticals Ltd and Morepen Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.